e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
Bronchiectasis and NTM infections: clinical and functional characterisation
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB)
Anthony De Soyza (Newcastle upon Tyne, United Kingdom), Anthony De Soyza, Timothy Aksamit, Elisabeth Operschall, Tiemo-Joerg Bandel, Ulrike Krahn, Margarita Criollo, Robert Wilson
Source:
International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Session:
Bronchiectasis and NTM infections: clinical and functional characterisation
Session type:
Thematic Poster Session
Number:
2617
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Anthony De Soyza (Newcastle upon Tyne, United Kingdom), Anthony De Soyza, Timothy Aksamit, Elisabeth Operschall, Tiemo-Joerg Bandel, Ulrike Krahn, Margarita Criollo, Robert Wilson. LATE-BREAKING ABSTRACT: Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB). Eur Respir J 2015; 46: Suppl. 59, 2617
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials
Related content which might interest you:
Baseline profiles of subjects randomised in RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-CF bronchiectasis (NCFB) by pathogen and prior exacerbation rate
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
LATE-BREAKING ABSTRACT: RESPIRE 1: Ciprofloxacin DPI 32.5mg b.d. administered 14 day on/off or 28 day on/off vs placebo for 48 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFB)
Source: International Congress 2016 – Clinical update on bronchiectasis
Year: 2016
Influence of severity on outcome in a phase II trial of ciprofloxacin DPI in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013
LATE-BREAKING ABSTRACT: Inhaled mannitol for non-cystic fibrosis bronchiectasis: results of a 12 month, multi-centre, double-blind, controlled study.
Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment
Year: 2013
Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline
Source: International Congress 2017 – Update on community acquired pneumonia
Year: 2017
Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013
Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Year: 2018
Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis
Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients
Year: 2013
A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic
pseudomonas aeruginosa
(PA) infection for pharmacokinetic and therapeutic equivalence
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
LATE-BREAKING ABSTRACT: Two Phase 3 placebo-controlled trials of Aztreonam Lysine for Inhalation (AZLI) for Non-Cystic Fibrosis Bronchiectasis (NCFB)
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum
pseudomonas aeruginosa
(
Pa
) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE)
Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis
Year: 2011
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials
Source: International Congress 2016 – Asthma management
Year: 2016
Longitudinal performance of the bronchiectasis severity index (BSI) in patients on regular intravenous (IV) antibiotic therapy for bronchiectasis
Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections
Year: 2016
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
Source: Eur Respir J 2013; 41: 1107-1115
Year: 2013
Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
Source: Eur Respir J, 51 (1) 1702052; 10.1183/13993003.02052-2017
Year: 2018
Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA)
Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook
Year: 2015
RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis
Source: Eur Respir J, 51 (1) 1702053; 10.1183/13993003.02053-2017
Year: 2018
Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA).
Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections
Year: 2017
A randomised placebo-controlled dose finding study of tobramycin inhalation powder (TIP) in patients with bronchiectasis (BE) and pulmonary P. aeruginosa Pa) infection (iBEST-1)
Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept